ClinicalTrials.gg
CompletedNCT01359696Updated Apr 12, 2017

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0425 Administered With and Without Gemcitabine in Patients With Refractory Solid Tumors or Lymphoma

A Phase 1 interventional study of GDC-0425 and gemcitabine in Solid Tumor, sponsored by Genentech, Inc.. Completed at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-04-12.

Sponsored by Genentech, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, Phase I, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of GDC-0425 administered with and without gemcitabine.

02

Conditions studied

  • Solid Tumor

Keywords

  • solid cancers
03

In context

Lead sponsor

Genentech, Inc. is the lead sponsor of 517 studies on the registry; 20 are open to participants now.

Of its 95 completed or terminated interventional studies of FDA-regulated products, 52 (55%) have results posted.

First submitted after Genentech, Inc. became part of Hoffmann-La Roche.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >= 18 years
  • (ECOG) performance status of 0 - 1
  • Signed Form
  • or cytologically documented, locally advanced or solid tumors or lymphoma for which standard therapy either does not exist or has proven ineffective or intolerable
  • Adequate hematologic and end-organ (liver and kidney) function
  • For female patients of and male patients with partners of childbearing potential, agreement by the patient that the patient and/or partner will use an effective form of
  • Patients enrolled in certain phases must be willing to provide fresh and/or

Exclusion criteria

Exclusion Criteria:

  • History of prior significant toxicity from a same class of agents as GDC-0425 or gemcitabine requiring discontinuation of treatment
  • Allergy, or to the GDC-0425 formulation or gemcitabine
  • Experimental therapy or anti-cancer therapy within 4 weeks prior to the first dose of study drug treatment
  • Radiotherapy within 2 weeks prior to first dose of study drug treatment
  • More than two regimens of cytotoxic chemotherapy for the treatment of locally advanced or cancer
  • History of receiving high-dose chemotherapy requiring bone marrow or stem cell support
  • History of receiving radiation to more than 25% of bone marrow-bearing areas
  • Acute drug-related toxicities from previous therapies have not resolved prior to study entry, except for alopecia and mild neuropathy
  • Current severe, uncontrolled systemic disease (including but not limited to cardiovascular, pulmonary, or renal disease or ongoing or active infection) excluding cancer
  • Significant heart disease and heart dysfunction including but not limited to uncontrolled severe hypertension, heart failure, and reduced cardiac contractility
  • Uncontrolled ascites, due to diseases other than cancer
  • Inability or unwillingness to swallow pills/capsules
  • History of malabsorption or other condition that would interfere with drug absorption
  • Any history of active stomach and/or intestine bleeding within the 6 months prior to screening
  • Known infection
  • Pregnancy, lactation, or breastfeeding
  • Known that are untreated, symptomatic, or require therapy to control symptoms
  • Inability to comply with study and follow up procedures
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    A

    Drug: GDC-0425 · Drug: gemcitabine

Interventions

  • DrugGDC-0425

    Oral escalating dose

  • Intravenous repeating dose

06

What researchers measure

Primary outcomes

  1. Incidence of all adverse events graded according to NCI CTCAE, v4.0

    Time frame: Up to 1 year

  2. Incidence of dose limiting toxicities (DLTs)

    Time frame: Up to 35 days

  3. Pharmacokinetic property of GDC-0425: determination of plasma drug concentration

    Time frame: Up to 12 months or early study discontinuation

  4. Pharmacokinetic property of GDC-0425: exposure

    Time frame: Up to 12 months or early study discontinuation

  5. Pharmacokinetic property of GDC-0425: half-life

    Time frame: Up to 12 months or early study discontinuation

  6. Severity of all adverse events graded according to NCI CTCAE, v4.0

    Time frame: Up to 1 year

Secondary outcomes

  1. Antitumor activity of GDC-0425 in combination with gemcitabine: determination of tumor response using RECIST v1.1 for patients with measurable disease

    Time frame: Up to 12 months or early study discontinuation

07

Study locations

3 sites
  • Karmanos Cancer Institute..
    Detroit, Michigan 48201, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Institut Gustave Roussy; Ser. de Med. Nucleaire; Cancerologie Endo
    Villejuif, 94805, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2011 to primary completion in May 2014, 34 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2011
First posted
May 25, 2011
StartActual
Jul 11, 2011
Primary completionActual
May 29, 2014
CompletionActual
May 29, 2014
Last update
Apr 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01359696
Lead sponsor
Genentech, Inc.
Responsible party
Sponsor
First posted
May 25, 2011
Start date
Jul 11, 2011
Primary completion
May 29, 2014
Completion
May 29, 2014
Last update
Apr 12, 2017

Study contacts

Chia Portera, M.D., Ph.D.
study director · Genentech, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gemcitabine

Start the discussion